$70.050
-0.287 (-0.41%)At close
RDNT News
RDNT Events
RadNet to Acquire Onrad for $350M
RadNet announced that it has entered into a definitive agreement to acquire Onrad. Onrad, through its more than 130 contracted radiologists, is a provider of teleradiology and in-hospital professional radiology staffing services for hospitals, health systems and other diagnostic imaging sites of care. The transaction is expected to close in early 2027 and is subject to customary regulatory review and closing conditions. Upon closing, Onrad shareholders will receive a cash payment of $350M and 5M shares of RadNet, Inc. common stock, subject to customary adjustments. In addition, an earnout of up to $210M in value will be payable upon achievement of target EBITDA for 2027. The earnout is payable in cash, RadNet common stock, or a combination thereof, at RadNet's election.
RadNet Partners with WIN-NextGen to Cultivate Medical Imaging Talent
RadNet announced a collaboration with WIN-NextGen, a workforce innovation network dedicated to cultivating talent across the 3S Workforce, to introduce middle school, high school and young adult learners to careers in medical imaging. The medical imaging profession is facing a workforce shortage as demand for diagnostic imaging continues to grow faster than the pipeline of future radiologists and radiologic technologists. Through RadNet's collaboration with WIN-NextGen, students aged 12 to 17 throughout Maryland, Washington, D.C. and parts of Virginia, as well as young adults ages 18 to 24, will gain access to WIN-NextGen's digital workforce platform featuring age-appropriate learning modules, interactive career experiences, mentorship opportunities and imaging center shadowing experiences. The collaboration is expected to expand over time to include internship and scholarship opportunities.
RadNet Reports Q2 Revenue of $622.7M, Beating Expectations
Reports Q2 revenue $622.7M, consensus $609.33M. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results. In the second quarter of 2026, Total Company Revenue grew 25.0% and Digital Health segment Revenue increased 56.5% from last year's same quarter. Growth was driven by strong increases in aggregate and same center procedural volumes, the contribution from recent acquisitions, a continuing shift in procedural volumes towards advanced imaging and incremental Digital Health sales and licenses of Enterprise Imaging and AI solutions."
RadNet Subsidiary DeepHealth Receives FDA 510(k) Clearance
DeepHealth, a wholly owned subsidiary of RadNet, last night announced FDA 510(k) clearance for DeepHealth Breast Ultrasound, an AI-powered solution that it says "brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging." The company added: "DeepHealth Breast Ultrasound automates lesion detection, characterization and reporting, streamlining sonographer and radiologist workflows in one intelligent experience. Together with its AI-powered mammography solutions, the expanded DeepHealth breast platform is the most comprehensive in the industry."
DeepHealth Receives FDA Approval for New Breast Imaging Features
DeepHealth, a wholly owned subsidiary of RadNet, announces it has received FDA 510(k) clearances for two new Breast Suite functionalities: Breast Arterial Calcification Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease; Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls. ProFound Pro with prior exam integration will be brought to market as Mammo Dx. The two additions reinforce Breast Suite as the industry's most comprehensive end-to-end breast imaging AI suite-a modular, interoperable portfolio of applications addressing real-world clinical needs across breast cancer screening and diagnostic pathways. Both newly FDA cleared functionalities are now commercially available in the United States.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.